A genetically modified tobacco plant has been developed to synthesize five psychedelics, notably DMT, psilocybin, and psilocin. This advancement could alter the landscape of psychedelic production.
The engineered plant leverages genetic modifications to enhance its capacity for producing these compounds, which have historical significance in various spiritual and therapeutic contexts.
The implications of this research extend to mental health treatment, potentially providing a more accessible means of producing psychedelics for therapeutic applications, though further studies will be necessary to evaluate practical deployment.